Result of Scrip Dividend & Application for ...
Amlin Plc
AMLIN PLC ('Amlin')
RESULT OF SCRIP DIVIDEND ALTERNATIVE OFFER AND APPLICATION FOR LISTING
Following the approval of the relevant resolution at the Annual General Meeting
earlier today, the scrip dividend alternative offer to Amlin's final dividend of
1.65p per share, made in a circular to shareholders dated 31 March 2004, is now
unconditional.
The Scrip Dividend Alternative was accepted in respect of 54,906,869 shares
which, at the reference price of 163.58p per share, will entitle the holders to
the issue of a total of 553,703 new ordinary shares of 25p each fully paid,
ranking, when issued, pari passu in all respects with Amlin's existing shares.
Application will be made to the UK Listing Authority and the London Stock
Exchange for these additional shares to be admitted to the Official List and to
trading. It is expected that such listing will become effective and that
dealings in the additional shares will commence on 25 May 2004.
Following the issue of the Scrip Dividend Alternative shares, the issued share
capital of Amlin will be 392,446,218 ordinary shares of 25p each.
19 May 2004
Enquiries:
Charles Pender 020 7746 1000
Secretary
Amlin plc
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.